Business Wire

ALTER-DOMUS

19.7.2022 09:02:07 CEST | Business Wire | Press release

Share
Leading Fund Administrator Alter Domus Appoints Gus Harris to its Group Executive Board

Alter Domus, a leading provider of integrated solutions for the alternative investment industry, today announced it has appointed Gus Harris, Head of AD Data & Analytics, to its Group Executive Board (GEB) where he will continue to report to Doug Hart, Chief Executive Officer.

In his current role, Gus leads Alter Domus’ data and analytics products strategy and team, developing new data assets and offerings to provide value-add solutions to alternatives market participants, including risk managers, investment managers, analysts and support functions at investor and asset manager clients. The team will help clients bring their data into a modern technology-enabled environment, allowing them to develop a competitive edge in their ability to efficiently generate meaningful and timely insights from their most crucial data sets.

As an extension to our data and analytics efforts, Gus is overseeing the development of proprietary applications into Software-as-a-Service (SaaS) products, which will further expand Alter Domus’ reach into the middle and front offices of their expanding client base. Early product development has focused on solutions which improve operational governance and efficiency for clients to more effectively risk-manage, monitor and grow their alternatives portfolios. The team has lined up several clients, including new clients, and strategic partnerships to accelerate their go-to-market and will have several newly built products by year-end.

Since joining Alter Domus last October, Gus has hired a world-class team to oversee the firm’s growth in this important area. The seasoned team, which has extensive experience building similar solutions for large financial institutions globally, brings together significant capabilities around modern big data, data science, technology, and product management disciplines. Team members have honed their skills at, and joined Alter Domus directly from, reputable institutions such as Amazon Web Services, Morgan Stanley, Moody’s Analytics, KPMG, and other established multinational organizations.

“Technology has been an integral part of the backbone of Alter Domus’ offering to clients, and Gus has brought an innovative and forward-thinking vision to our data and analytics services. Clients are under increasing pressure to better manage and exploit data, which makes Gus’ voice and perspective at a group executive level particularly important,” said Doug Hart . “Gus brings a strong sense of leadership, collegiality, and considerable expertise to our leadership team, key traits which have helped to catalyze his team’s growth and offering in a relatively short period of time.”

“I am proud to join Alter Domus’ group executive board, and I look forward to partnering with this talented and dynamic group of executive leaders. Alter Domus’ data and analytics team, which is comprised of seasoned and proven industry professionals, is undergoing tremendous growth and is already engaging with leading general and limited partners in the private equity, private debt – including CLO managers and investors – and commercial real estate sectors on complex and important projects,” said Gus Harris . “This reflects the increasingly important role that data and analytics will play in the future of our business, and the alternative investment industry as a whole. As the marketplace matures, demand for ‘better data’ will only continue to grow, and we are extremely well-positioned to support the market on this transformational journey. With technology running across the spectrum of our data solutions – from collection, to analytics, to delivery – we’re thrilled to be helping clients define the standards that will set their business on a solid foundation for sustainable future growth.”

Prior to joining Alter Domus in September 2021, Gus was a founding executive of Moody’s Analytics where he helped build several flagship products and services including Moody’s structured-finance products, ESG data and research services, Moody’s DataHub (DaaS), and other SaaS tools. Gus is a CPA and CFA charter holder and completed advanced degrees in finance from Columbia Business School, risk and statistics from New York University’s Stern School of Business, and technology from Pace University.

About Alter Domus

Alter Domus is a leading provider of integrated solutions, serving private equity, real assets and debt capital markets sectors with more than 3,600 employees across 36 offices globally. Solely dedicated to alternatives, Alter Domus offers fund administration, corporate services, depositary services, capital administration, transfer pricing, domiciliation, management company services, loan administration, agency services, trade settlement and CLO manager services. Find out more at www.alterDomus.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye